# An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma

> **NCT00738582** · PHASE2 · COMPLETED · sponsor: **Morphotek** · enrollment: 89 (actual)

## Conditions studied

- Malignant Pleural Mesothelioma

## Interventions

- **DRUG:** MORAb-009 (Amatuximab)
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00738582
- **Lead sponsor:** Morphotek
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-31
- **Primary completion:** 2011-06-30
- **Final completion:** 2014-01-10
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2022-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00738582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00738582, "An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00738582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*